News

2017 Sep 19

Phase II Study of Additional Treatment in Patients With Non-Hodgkin Lymphoma Shows No Significant Benefit

A phase II trial reported in the Journal of Clinical Oncolo gy by John P. Leonard, M.D., and collaborators showed no significant progression-free survival benefit of adding bortezomib to R-CHOP. Read more

2017 Sep 18

Epigenetic Code Plays a Role in Acute Myeloid Leukemia

This article by Bridget Kuehn first appeared in the Cornell Chronicle . Errors in the regulation of gene expression may contribute to the development of a common form of blood cancer and point to potential treatment... Read more

2017 Sep 15

Olivier Elemento, PhD, Appointed Director of the Englander Institute for Precision Medicine

Dr. Olivier Elemento , a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill... Read more

2017 Sep 15

Double Targeting Ligands to Identify and Treat Prostate Cancer

John Babich, PhD, and collaborators have demonstrated a new way to identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. Read the featured basic article of the September... Read more

Neuroendocrine prostate cancer cells from a patient biopsy. Image credit: Dr. Loredana Puca

2017 Sep 07

Weill Cornell Medicine Awarded $11.3 Million Prestigious Grant for Prostate Cancer Research

NEW YORK (September 7, 2017) — Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), part of the National... Read more

prostate cancer neuroendocrine spore rubin beltran NEPC

2017 Sep 07

Meyer Cancer Center Investigators Awarded $11.3 Million Prestigious Grant for Prostate Cancer Research

The Weill Cornell Medicine Specialized Programs of Research Excellence (SPORE) in Prostate Cancer, led by Mark Rubin, M.D., has been funded by the National Cancer Institute (NCI). Read more

2017 Aug 31

The most important lesson I learned from a patient: Optimism Leads to Achievement

Brendon Stiles, M.D., reflects on his experience with an inspiring young patient. Read more

2017 Aug 30

Impact of the FDA Approval of CTL019 in ALL

Gail J. Roboz, M.D., discusses the impact of the FDA approval of tisagenlecleucel (CTL019; Kymriah) in select pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Read more

2017 Aug 30

Drug may curb female infertility from cancer treatments

An existing drug may one day protect premenopausal women from life-altering infertility that commonly follows cancer treatments, according to a study by Ithaca member John Schimenti, Ph.D. Read more

2017 Aug 29

The next steps for biopsies in prostate cancer

Jim Hu, M.D., MPH, discusses the next steps of biopsies for patients with prostate cancer. Read more

2017 Aug 28

Retinoids’ Extraordinary Potential

Feature about Lorraine Gudas, Ph.D., who is studying the role of Vitamin A and retinoic acid in cancer and other diseases. Read more

2017 Aug 25

Symposium addresses role of truth in universities, society

Holly Prigerson, Ph.D., spoke about the role of truth in their fields and in society during an academic symposium to celebrate the inauguration of Cornell's 14th president, Martha E. Pollack. Read more

2017 Aug 25

Immunotherapy gains traction as potential malignant pleural mesothelioma treatment

Ashish Saxena, M.D., Ph.D., comments on the results of a study on the use of immunotherapy to treat patients with the lung cancer mesothelioma. Read more

2017 Aug 25

Evolving paradigms in AML treatment

Gail Roboz, M.D., discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML). Read more

2017 Aug 24

Precision medicine in hematologic malignancies

John P. Leonard, M.D., discusses the advance of precision medicine across hematologic malignancies. Read more

David Nanus, M.D., discusses cancer drug prices

2017 Aug 24

Early stage kidney cancer treatment

David M. Nanus, M.D., discusses treatment for patients with early-stage kidney cancer. Read more

2017 Aug 23

A million dollars in Movember money funds advanced prostate cancer research

Meyer prostate cancer experts led by Scott Tagawa, M.D., will use Movember funds to investigate a new treatment for an advanced form of the disease. Read more

Howard Fine, M.D., is creating 'mini brains' in his lab at Meyer Cancer Center

2017 Aug 23

Research trial in NYC may change course of brain tumor treatment

Howard Fine, M.D., is determined to change the course of glioblastoma treatment, by testing drugs on 'mini brains' created in the lab. Read more

2017 Aug 18

Potential of immunotherapy in MCL landscape

Peter Martin, M.D., discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL). Read more

Manish Shah, M.D., gastrointestinal oncology expert at the Meyer Cancer Center of Weill Cornell Medicine

2017 Aug 18

Exploring the decreasing incidence of colon cancer in those over the age of 50

Manish A. Shah, M.D., discusses the decreasing incidence of colon cancer diagnosis in those over the age of 50. Read more

News

Phase II Study of Additional Treatment in Patients With Non-Hodgkin Lymphoma Shows No Significant Benefit

Epigenetic Code Plays a Role in Acute Myeloid Leukemia

Olivier Elemento, PhD, Appointed Director of the Englander Institute for Precision Medicine

Double Targeting Ligands to Identify and Treat Prostate Cancer

Weill Cornell Medicine Awarded $11.3 Million Prestigious Grant for Prostate Cancer Research

Meyer Cancer Center Investigators Awarded $11.3 Million Prestigious Grant for Prostate Cancer Research

The most important lesson I learned from a patient: Optimism Leads to Achievement

Impact of the FDA Approval of CTL019 in ALL

Drug may curb female infertility from cancer treatments

The next steps for biopsies in prostate cancer

Retinoids’ Extraordinary Potential

Symposium addresses role of truth in universities, society

Immunotherapy gains traction as potential malignant pleural mesothelioma treatment

Evolving paradigms in AML treatment

Precision medicine in hematologic malignancies

Early stage kidney cancer treatment

A million dollars in Movember money funds advanced prostate cancer research

Research trial in NYC may change course of brain tumor treatment

Potential of immunotherapy in MCL landscape

Exploring the decreasing incidence of colon cancer in those over the age of 50

Follow us on X

2022 Annual Report

2021 Annual Report

2018 Annual Report

2017 Annual Report

2016 Annual Report

Newsletters